CA2370401A1 - Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant - Google Patents
Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant Download PDFInfo
- Publication number
- CA2370401A1 CA2370401A1 CA002370401A CA2370401A CA2370401A1 CA 2370401 A1 CA2370401 A1 CA 2370401A1 CA 002370401 A CA002370401 A CA 002370401A CA 2370401 A CA2370401 A CA 2370401A CA 2370401 A1 CA2370401 A1 CA 2370401A1
- Authority
- CA
- Canada
- Prior art keywords
- phenoxazin
- ethoxy
- phenyl
- ethoxypropanoic acid
- arginine salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne de nouvelles formes polymorphes/pseudompolymorphes d'un sel arginine d'acide 3-[4-[2-(phénoxazine-10-yl)éthoxy]phényl]-2-éthoxypropanoïque de formule (I). L'invention concerne aussi une composition pharmaceutique comprenant les nouvelles formes polymorphes ou leur mélange et un support pharmaceutiquement acceptable. Les formes polymorphes sont plus actives comme agent antidiabétique et hypolipidémique que le nouvel acide 3-[4-[2-(phénoxazin-10-yl)éthoxy]phényl]-2-éthoxypropanoïque.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1999/000681 WO2000063191A1 (fr) | 1999-04-16 | 1999-04-16 | Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres |
IBPCT/IB99/00681 | 1999-04-16 | ||
IN436/MAS/99 | 1999-04-19 | ||
IN436MA1999 | 1999-04-19 | ||
PCT/IB2000/000470 WO2000063192A1 (fr) | 1999-04-16 | 2000-04-17 | Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2370401A1 true CA2370401A1 (fr) | 2000-10-26 |
Family
ID=26318745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002370401A Abandoned CA2370401A1 (fr) | 1999-04-16 | 2000-04-17 | Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1171430A1 (fr) |
CN (1) | CN1351597A (fr) |
AU (1) | AU3831300A (fr) |
BG (1) | BG106022A (fr) |
BR (1) | BR0010683A (fr) |
CA (1) | CA2370401A1 (fr) |
CZ (1) | CZ20013711A3 (fr) |
EE (1) | EE200100529A (fr) |
HR (1) | HRP20010748A2 (fr) |
HU (1) | HUP0200758A3 (fr) |
IL (1) | IL145958A0 (fr) |
MX (1) | MXPA01010472A (fr) |
NO (1) | NO20015016L (fr) |
PL (1) | PL351492A1 (fr) |
RU (1) | RU2001130883A (fr) |
TR (1) | TR200103851T2 (fr) |
WO (1) | WO2000063192A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE309818T1 (de) | 2000-03-08 | 2005-12-15 | Novo Nordisk As | Senkung des serum cholesterols |
US6897199B2 (en) * | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
WO2003031432A1 (fr) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Nouvelles piperidines substituees |
US20030171411A1 (en) | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
JP5142448B2 (ja) * | 2002-04-19 | 2013-02-13 | ファエス・ファルマ・ソシエダッド・アノニマ | 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体 |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
WO2004101505A1 (fr) | 2003-05-14 | 2004-11-25 | Novo Nordisk A/S | Nouveaux composes pour le traitement de l'obesite |
WO2005030797A2 (fr) | 2003-09-30 | 2005-04-07 | Novo Nordisk A/S | Nouveaux agonistes du recepteur de la melanocortine |
JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
SI1723128T1 (sl) | 2004-01-06 | 2013-04-30 | Transtech Pharma, Inc. | Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze |
WO2005105785A2 (fr) | 2004-05-04 | 2005-11-10 | Novo Nordisk A/S | Nouveaux derives d'indole |
EP2316446A1 (fr) | 2004-06-11 | 2011-05-04 | Novo Nordisk A/S | Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1 |
CN101060856B (zh) | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | 可溶、稳定的含胰岛素制剂 |
CA2590720A1 (fr) | 2004-12-03 | 2006-06-08 | Lone Jeppesen | Composes heteroaromatiques activants de glucokinase |
JP5121707B2 (ja) | 2005-07-04 | 2013-01-16 | ハイ ポイント ファーマシューティカルズ,エルエルシー | 新規医薬 |
ES2422383T3 (es) | 2005-07-14 | 2013-09-11 | Novo Nordisk As | Activadores de urea glucoquinasa |
US8106090B2 (en) | 2005-07-20 | 2012-01-31 | Eli Lilly And Company | 1-amino linked compounds |
WO2007123581A1 (fr) | 2005-11-17 | 2007-11-01 | Eli Lilly And Company | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques |
AU2007229492B2 (en) | 2006-03-28 | 2011-11-03 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
SG163547A1 (en) | 2006-05-29 | 2010-08-30 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
CA2669874A1 (fr) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Nouvelles 2-(2-hydroxyphenyl) benzothiadiazines utilisees pour traiter l'obesite et le diabete |
ATE523497T1 (de) | 2006-11-15 | 2011-09-15 | High Point Pharmaceuticals Llc | Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体 |
BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
WO2011104378A1 (fr) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides de traitement de l'obésité |
BR112012024379A2 (pt) | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
EP2670368A4 (fr) | 2011-02-03 | 2015-04-15 | Pharmedica Ltd | Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète |
AU2012234276A1 (en) | 2011-03-28 | 2013-08-29 | Novo Nordisk A/S | Novel glucagon analogues |
MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
JP2020514365A (ja) | 2017-03-15 | 2020-05-21 | ノヴォ ノルディスク アー/エス | メラノコルチン4受容体に結合可能な二環式化合物 |
WO2019219714A1 (fr) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Composés capables de se lier au récepteur de la mélanocortine 4 |
WO2020053414A1 (fr) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
IN182496B (fr) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
FR2746099B1 (fr) * | 1996-03-13 | 1998-04-30 | Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique | |
EP0844997A1 (fr) * | 1996-06-19 | 1998-06-03 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation |
WO1999019313A1 (fr) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
JP2002501909A (ja) * | 1998-01-29 | 2002-01-22 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物 |
PL341795A1 (en) * | 1998-05-27 | 2001-05-07 | Reddy Research Foundation | Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds |
-
2000
- 2000-04-17 MX MXPA01010472A patent/MXPA01010472A/es unknown
- 2000-04-17 EE EEP200100529A patent/EE200100529A/xx unknown
- 2000-04-17 EP EP00917222A patent/EP1171430A1/fr not_active Withdrawn
- 2000-04-17 BR BR0010683-6A patent/BR0010683A/pt not_active IP Right Cessation
- 2000-04-17 RU RU2001130883/04A patent/RU2001130883A/ru unknown
- 2000-04-17 CN CN00807705A patent/CN1351597A/zh active Pending
- 2000-04-17 WO PCT/IB2000/000470 patent/WO2000063192A1/fr active Search and Examination
- 2000-04-17 PL PL00351492A patent/PL351492A1/xx not_active Application Discontinuation
- 2000-04-17 CZ CZ20013711A patent/CZ20013711A3/cs unknown
- 2000-04-17 CA CA002370401A patent/CA2370401A1/fr not_active Abandoned
- 2000-04-17 TR TR2001/03851T patent/TR200103851T2/xx unknown
- 2000-04-17 IL IL14595800A patent/IL145958A0/xx unknown
- 2000-04-17 HU HU0200758A patent/HUP0200758A3/hu unknown
- 2000-04-17 AU AU38313/00A patent/AU3831300A/en not_active Abandoned
-
2001
- 2001-10-15 HR HR20010748A patent/HRP20010748A2/hr not_active Application Discontinuation
- 2001-10-15 NO NO20015016A patent/NO20015016L/no not_active Application Discontinuation
- 2001-10-16 BG BG106022A patent/BG106022A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
BR0010683A (pt) | 2003-07-01 |
TR200103851T2 (tr) | 2002-04-22 |
EE200100529A (et) | 2002-12-16 |
WO2000063192A1 (fr) | 2000-10-26 |
MXPA01010472A (es) | 2002-05-06 |
NO20015016D0 (no) | 2001-10-15 |
RU2001130883A (ru) | 2004-03-20 |
HUP0200758A2 (hu) | 2002-07-29 |
IL145958A0 (en) | 2002-07-25 |
EP1171430A1 (fr) | 2002-01-16 |
CN1351597A (zh) | 2002-05-29 |
PL351492A1 (en) | 2003-04-22 |
BG106022A (bg) | 2002-04-30 |
HUP0200758A3 (en) | 2003-07-28 |
AU3831300A (en) | 2000-11-02 |
CZ20013711A3 (cs) | 2002-07-17 |
NO20015016L (no) | 2001-12-11 |
HRP20010748A2 (en) | 2003-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2370401A1 (fr) | Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant | |
JP2003508348A (ja) | 新規多型形態の抗糖尿病薬剤:それらの製造方法およびそれらを含有する医薬組成物 | |
WO2000063193A1 (fr) | Nouvelles formes polymorphes d'un agent antidiabetique: leur procede de preparation et composition pharmaceutique contenant lesdites formes | |
ZA200106994B (en) | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them. | |
CA2426117A1 (fr) | Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe | |
US6528507B1 (en) | Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
WO2002028857A1 (fr) | Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques | |
US20040068116A1 (en) | Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
US6897199B2 (en) | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds | |
WO2002062798A2 (fr) | Sels de composes heterocycliques pharmaceutiquement acceptables | |
US20020169175A1 (en) | Pharmaceutically acceptable salts of heterocyclic compounds | |
EP1623984A1 (fr) | Polymorphe I du sel de potassium de 5-[4-[[3-methyle-4-oxo-3,4-dihydroquinazoline-2yl]methoxy]benzyle]thiazolidine-2,4-dione | |
WO2002030914A1 (fr) | Sels de derives de benzothiazine et de benzoxazine et compositions pharmaceutiques a base de ces sels | |
AU2001291232A1 (en) | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
AU2001291232B2 (en) | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
WO2003066612A1 (fr) | Nouvelles formes polymorphes d'agents bicycliques antidiabetiques, leur procede de preparation et compositions pharmaceutiques les contenant | |
US20020142993A1 (en) | Pharmaceutically acceptable salts of bicyclic compounds | |
WO2003006022A1 (fr) | Derives de tetrahydroquinoline et leur utilisation en medecine, procede de preparation associe et compositions pharmaceutiques contenant lesdits composes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |